NCT06133426 Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients
| NCT ID | NCT06133426 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Lymphoma, Non-Hodgkin |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-09-04 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-09-04 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this research, we will evaluate the feasibility of following by remote monitoring, using a connected scale, in hematology patients suffering from myeloma or lymphoma and requiring treatment with chemotherapy. 30 patients will be included in the research and will all use a connected scale for the duration of their participation (7 weeks +/- 1 week). During their participation, patients will be asked to weigh themselves once a day, ideally at a set time. Patient data will be accessible by the medical team via a remote monitoring platform. Alerts will be generated in the event of abnormal development of certain clinical parameters (weight, heart rate, etc.) allowing early treatment to be implemented by the medical team. At the end of their participation, we will evaluate patients' support and perception of this tool, as well as the healthcare consequences of the alerts generated by the remote monitoring platform.
Eligibility Criteria
Inclusion Criteria: * Patient aged 18 and over (male or female) * Patient suffering from aggressive non-Hodgkin's lymphoma or multiple myeloma with a plan for systemic chemotherapy or having started two cycles or less or patient with the need for therapeutic intensification under the cover of autograft in the context of myeloma or lymphoma * Patient who can be contacted by telephone during their participation in the research * Patient able to return home at the end of their initial hospitalization * Patient affiliated to social security * Patient able to read and speak French * Patient having signed free, informed and written consent Exclusion Criteria: * Patient with an estimated life expectancy \< 3 months * Patient with moderate to severe cognitive impairment (assessed by MMSE \< 20) * Patient with a psychiatric or physical disability that does not allow the use of the device * Patient with a pacemaker * Patient participating in another intervention research project * Pregnant patient * Patient deprived of liberty * Patient under legal protection (guardianship or curatorship)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06133426 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lymphoma, Non-Hodgkin. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06133426 currently recruiting?
Yes, NCT06133426 is actively recruiting participants. Contact the research team at rudy.birsen@aphp.fr for enrollment information.
Where is the NCT06133426 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT06133426 clinical trial?
NCT06133426 is sponsored by Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 30 participants.